surmount-1 tirzepatide non-diabetic weight loss SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, SURMOUNT-1 (NEJM 2022) tested tirzepatide
Description
Some patients also report headaches , gastrointestinal discomfort , anxiety , and sleep disturbances
Aim for 8 to 10 glasses of water daily , or approximately 2 to 2.5 litres
*These statements have not been evaluated by the Food and Drug Administration
In the UK/US, private clinics often offer it for menopause weight gaineven without diabetes
Semaglutide is marketed under three brand names to distinguish different indications and formulations: Ozempic (injectable for diabetes), Wegovy (injectable for obesity), and Rybelsus (oral for diabetes)
